Kidneys and Genito-Urinary System Overactive Bladder

Table of Contents

UPCOMING PATENT EXPIRES BY THERAPY AREA
Overactive Bladder Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects

--Top Companies in late stage Overactive Bladder Projects
--Antares Pharma Inc
--Allergan Inc
--Avera Pharmaceuticals, Inc.
--Astellas Pharma Inc
--BioXell S.p.A.
--Barr Pharmaceuticals Inc
--elbion NV
--Dainippon Sumitomo Pharma Co., Ltd.
--Kyorin Co., Ltd.
--GlaxoSmithKline plc
--Mitsubishi Tanabe Pharma Corporation
--Merck & Co Inc
--Pfizer Inc
--Nippon Shinyaku Co., Ltd.
--Ranbaxy Laboratories Ltd.
--Plethora Solutions Limited
--Sanofi-Aventis
--RECORDATI SpA
--Watson Pharmaceuticals Inc
--UroGene

--Top Companies in early stage Overactive Bladder Projects
--Auxilium Pharmaceuticals Inc
--Dynogen Pharmaceuticals, Inc.
--Eisai Co Ltd
--GlaxoSmithKline plc
--Melior Discovery, Inc.
--Omeros Corporation
--Ono Pharmaceutical Co., Ltd.
--Ranbaxy Laboratories Ltd.
--Roche Holdings Ltd
--Urigen Pharmaceuticals, Inc.
--Xention Limited
--erly Xention Discovery Ltd)

Pipeline Revenue
--Pipeline Revenue
Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--Pending Approval Pipeline View
--Post Marketing Pipeline View
--On the Market Pipeline View
--Discovery/Development Pipeline View